MOLOGEN AG: 2011 annual financial statements - very good basis for the 2012 financial year

Press Release No. 4/2012 of 03/30/2012

MOLOGEN AG: 2011 annual financial statements - very good basis for the 2012 financial year

- Study results for MGN1601 much better than expected

- First results from colorectal cancer study with MGN1703 imminent

- Product pipeline expanded by lung cancer indication for MGN1703

The Berlin biotechnology company MOLOGEN AG made important advances also in the 2011 financial year, which were continued in the first quarter of 2012. As reported by the company upon presentation of its 2011 annual report, the financing of current research activities is ensured by two successful capital increases in January 2011 and March 2012. In Research & Development, the drug candidate MGN1601 produced very good clinical study results. In the 2nd quarter of 2012 the company will also present the first results from the ongoing colorectal cancer study with the most advanced compound MGN1703.

Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG: 'From an economic perspective, we remain on very sound footings and have the necessary means to continue our research work beyond the current financial year. We have also made good progress in the field of research: the study results shown in 2011 for MGN1601 attest to the excellent tolerability of our cell-based renal cancer therapy. Furthermore, we have been able to observe a clear survival benefit for patients in this study that far exceeded our expectations. With regard to the colorectal cancer medicament MGN1703, we are hoping for clear stimuli from the upcoming first results for the ongoing licensing discussions with the pharmaceutical industry. These are a few examples from our portfolio that allow me to take an optimistic look ahead at the current financial year.'

Treatment with MGN1601 gives patients survival benefit
At the end of 2011, MOLOGEN was able to finalize patient recruitment for the phase I/II clinical study in the renal cancer indication with the assent of the responsible authorities. The first evaluation revealed excellent results with regard to safety and tolerability. In the further course of the study, MOLOGEN was now also able to demonstrate a clear survival benefit for the treated patients that exceeded expectations. The preliminary median survival time of the already seriously ill patients that were able to complete the specified study therapy scheme with MGN1601 substantially exceeded the anticipated five to seven months with a preliminary result of more than ten months.

First results from colorectal cancer study with MGN1703 imminent
It is anticipated that the first results from the colorectal cancer study with MOLOGEN's most advanced product candidate, the cancer immunotherapy MGN1703, will be submitted at the end of April 2012. The company has initiated the necessary preparations. The randomized, blinded, placebo-controlled phase II/III clinical study is currently performed in various European countries and in Russia.

Expenditure on research & development increases as planned in 2011
In the 2011financial year, primarily the ongoing clinical studies - for MGN1703 in the indication of colorectal cancer and for MGN1601 with renal cancer - led to a planned increase in expenditure on research & development. Added to this was the extension of the product pipeline, as MGN1703 will now also be tested in the indication of lung cancer. Intensive preparations had already commenced in the previous financial year. Hence, in comparison with the previous year, total expenditure on R&D increased to 6.1 million Euros, that is, by about 40 percent. The monthly cash burn rate correspondingly increased in 2011 to 0.6 million Euros.

On the income side, as in the previous year, MOLOGEN recorded revenues of 0.1 million Euros. To this were added other operating income, which increased by 0.3 million Euros in comparison with the previous year due to received subsidies for ongoing research to a total of 0.7 million Euros. In all, losses for the 2011 financial year amounted to 7.5 million Euros, which is within planned parameters. The balance sheet on the reporting date of December 31, 2011 shows liquid funds of 7.5 million Euros, sufficient to finance current research work.

The complete annual report of MOLOGEN AG is available for download at the newly-designed company website: www.mologen.com

About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.
The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime Standard of the German stock exchange.

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.

MOLOGEN AG

PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner@mologen.com

INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor@mologen.com

External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.